- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Reviva Pharmaceuticals Unusual Options Activity | 2 | Benzinga.com | ||
| Di | Traders Buy Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) | 3 | MarketBeat | ||
| 11.01. | Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of "Buy" by Analysts | 2 | MarketBeat | ||
| 07.01. | Reviva Pharmaceuticals: Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit | 2 | GlobeNewswire (USA) | ||
| 17.12.24 | Reviva announces pricing of $18M public offering of common stock and warrants | 16 | Seeking Alpha | ||
| 16.12.24 | Reviva Pharmaceuticals: Reviva Announces Proposed Public Offering | 3 | GlobeNewswire (USA) | ||
| 16.12.24 | Reviva's antipsychotic shows promise against schizophrenia symptoms in year-long study | 3 | FierceBiotech | ||
| 16.12.24 | Reviva reports positive 1-year schizophrenia drug trial data | 3 | Investing.com | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.12.24 | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 14.11.24 | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 197 | GlobeNewswire (Europe) | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| 14.11.24 | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | Reviva vermeldet Fortschritte bei Studie zur Schizophrenie-Behandlung | 4 | Investing.com Deutsch | ||
| 08.10.24 | Reviva Pharmaceuticals: Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 07.10.24 | Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst | 32 | Benzinga.com | ||
| 02.10.24 | Reviva Pharmaceuticals: Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 3 | GlobeNewswire (USA) | ||
| 26.09.24 | Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference | 1 | GlobeNewswire (USA) | ||
| 23.09.24 | EF Hutton setzt Kaufempfehlung für Reviva Pharmaceuticals-Aktien | - | Investing.com Deutsch | ||
| 23.09.24 | EF Hutton sets Buy rating on Reviva Pharmaceuticals shares | 1 | Investing.com | ||
| 17.09.24 | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.09.24 | Reviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia | 321 | GlobeNewswire (Europe) | - Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal... ► Artikel lesen |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 21,440 | +0,75 % | Die missliche Lage von Bayer zieht weitere Kreise und anscheinend wird über einen Austausch der Wirtschaftsprüfer von PwC nachgedacht | Erst im Jahr 2021 erhielt PwC den Auftrag, künftig die Abschlüsse von BayWa zu überprüfen und üblicherweise wird ein solches Mandat für rund ein Jahrzehnt vergeben. In diesem Fall könnte ein Ende aber... ► Artikel lesen | |
| ROCHE | 286,05 | +1,34 % | Roche Aktie: Investment mit Zukunft! | Die Aktie des Schweizer Pharmagiganten verzeichnete am Dienstag eine bemerkenswerte Entwicklung an der Börse. Im Handelsverlauf konnte das Wertpapier einen Anstieg von 1,2 Prozent verbuchen und erreichte... ► Artikel lesen | |
| VIATRIS | 10,845 | -0,14 % | Viatris-Aktie: Kurs heute im Minus (10,8872 €) | Das Wertpapier von Viatris notiert am Mittwoch ein wenig leichter. Der jüngste Kurs betrug 11,20 US-Dollar. Für die Aktie von Viatris steht gegenwärtig ein Minus von 4,44 Prozent zu Buche. Das Papier... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 7,135 | -0,21 % | Green Thumb Industries: Survey Finds More Adults Turn to Cannabis Than Prescription Sleep Aids To Help Them Sleep | ||
| TONIX PHARMACEUTICALS | 0,236 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,586 | +2,62 % | Cassava Sciences, Inc.: Cassava Sciences Provides a Business Update | Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 10,260 | -0,39 % | Community-Rückblick: wO-User zu Newron Pharma nach Südkorea Deal: "2028 ist die Firma Geschichte..." | © Foto: ChatGPTDie Diskussion um Newron Pharma flammte erneut auf, nachdem die italienische Biotechfirma am 09.01. die Kooperation mit "Myung In Pharm", zwecks Vertrieb des Hoffnungsmittels Evenamide... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,883 | +1,67 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis | SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,185 | -1,27 % | Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 | ||
| COMPASS PATHWAYS | 3,440 | -1,71 % | Compass Pathways plc: Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer | Newly created role of Chief Patient Officer reinforces Compass' vision of working to achieve broad and equitable access to COMP360, if approved
Compass Pathways plc (Nasdaq: CMPS) ("Compass"),... ► Artikel lesen | |
| OPUS GENETICS | 1,120 | +1,82 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,470 | +0,62 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| SCYNEXIS | 1,064 | +4,11 % | SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections | JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 1,410 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA | SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update... ► Artikel lesen | |
| LIPOCINE | 4,680 | +6,36 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,005 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
